Medline Q3 net sales rise 10.4% to $7.9 billion; net income dips 1.2%, organic sales guidance raised
Medline reported third quarter 2026 net sales of $7.9 billion, up 10.4%, while net income fell 1.2% to $318 million, with the company citing higher inventory costs, operating expenses and customer mix, partly offset by $81 million of net IEEPA tariff refund benefits. The company raised its full-year 2026 Organic Sales growth outlook to 10.0% to 10.5%, reaffirmed Adjusted EBITDA guidance of $3.3 billion to $3.4 billion, and its board authorized a $1 billion share repurchase program.
Key points
- Q3 2026 net income was $318 million, down from $322 million; diluted EPS was $0.22
- Q3 2026 Adjusted EBITDA rose 11.8% to $960 million from $859 million
- Full-year 2026 Organic Sales growth guidance raised to 10.0% to 10.5% from 9.0% to 10.0%; Adjusted EBITDA guidance reaffirmed at $3.3 billion to $3.4 billion
- Board approved a $1 billion share repurchase program in October 2026, and $750 million of the 2033 Refinancing Term Loan Facility was prepaid
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.